Benitec Biopharma Inc. Common Stock (BNTC) is a publicly traded Healthcare sector company. As of May 21, 2026, BNTC trades at $10.99 with a market cap of $374.12M and a P/E ratio of -10.37. BNTC moved +2.99% today. Year to date, BNTC is -7.57%; over the trailing twelve months it is -21.11%. Its 52-week range spans $8.49 to $17.15. Analyst consensus is strong buy with an average price target of $25.00. Rallies surfaces BNTC's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Benitec Biopharma Reports Durable BB-301 Responses at 24 Months and $184.8M Cash: Benitec Biopharma reported durable 12- and 24-month responses to low dose BB-301 and further improvements at 3 months for high dose in its Phase 1b/2a OPMD study, with no treatment-related severe adverse events observed. The company holds $184.8 million in cash to fund BB-301 pivotal study design and 2H-2026 interim updates.
| Metric | Value |
|---|---|
| Price | $10.99 |
| Market Cap | $374.12M |
| P/E Ratio | -10.37 |
| EPS | $-1.05 |
| Dividend Yield | 0.00% |
| 52-Week High | $17.15 |
| 52-Week Low | $8.49 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-37.92M |
| Gross Margin | 0.00% |
4 analysts cover BNTC: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $25.00.